🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

205 results for “group” Clear

  1. OMP-18R5

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 mab completed

    1 trial

  2. OMP-21M18

    Mereo BioPharma Group plc

    Colorectal Cancer

    phase 1 small molecule completed

    1 trial

  3. OMP-21M18

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  4. OMP-305B83

    Mereo BioPharma Group plc

    Advanced Solid Tumor Malignancies

    phase 1 small molecule completed

    1 trial

  5. OMP-305B83

    Mereo BioPharma Group plc

    Cancer Ovaries

    phase 1 small molecule completed

    1 trial

  6. OMP-305B83

    Mereo BioPharma Group plc

    Metastatic Colorectal Cancer

    phase 1 small molecule terminated

    1 trial

  7. OMP-313M32

    Mereo BioPharma Group plc

    Locally Advanced Cancer

    phase 1 small molecule terminated

    1 trial

  8. OMP-336B11

    Mereo BioPharma Group plc

    Locally Advanced Malignant Neoplasm

    phase 1 small molecule terminated

    1 trial

  9. OMP-52M51

    Mereo BioPharma Group plc

    Relapsed or Refractory Lymphoid Malignancies

    phase 1 small molecule completed

    1 trial

  10. OMP-52M51

    Mereo BioPharma Group plc

    Relapsed or Refractory Solid Tumors

    phase 1 small molecule completed

    1 trial

  11. OMP-54F28

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 mab completed

    1 trial

  12. OMP-54F28 with Sorafenib

    Mereo BioPharma Group plc

    Hepatocellular Cancer

    phase 1 small molecule completed

    1 trial

  13. OMP-54F28, Nab-Paclitaxel and Gemcitabine

    Mereo BioPharma Group plc

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  14. OMP-54F28, Paclitaxel and Carboplatin

    Mereo BioPharma Group plc

    Ovarian Cancer

    phase 1 small molecule completed

    1 trial

  15. OMP-59R5

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  16. Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.

    The George Institute

    Diabetic retinopathy.

    phase 1 other active

    1 trial

  17. Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.

    The George Institute

    Diabetic retinopathy.

    phase 1 other active

    1 trial

  18. Pyrotinib low dose group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 1 small molecule active

    1 trial

  19. Recombinant SARS-CoV-2 Fusion Protein Vaccine

    Livzon Pharmaceutical Group

    COVID19

    phase 1 mab completed

    1 trial

  20. Safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous and subcutaneous multiple rising doses of BI 765250 versus placebo in trial participants with moderate to severe plaque psoriasis (double-blind, randomised, placebo-controlled, parallel-group design)

    Boehringer Ingelheim

    Plaque psoriasis

    phase 1 other active

    1 trial

  21. TP-05 (lotilaner oral), fasted group

    Tarsus Pharmaceuticals

    Healthy

    phase 1 small molecule completed

    1 trial

  22. TQF3250 placebo

    Chia Tai Tianqing Pharmaceutical Group Co.,

    Hyperglycemia

    phase 1 small molecule active

    1 trial

  23. The 10mg dose group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  24. The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in the treatment of type 2 diabetes mellitus when the condition cannot be adequately controlled by diet and exercise alone.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects).

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources